Resistance to first-line antibiotic piperacillin/tazobactam to grow from 12% to 25% in the UK by 2033

Posted on Feb 21, 2024

Airfinity models show that resistance of Acinetobacter baumannii bacteria to the first-line treatment antibiotic piperacillin/tazobactam is forecast to increase to 18.6% based on current trends and rise to 25% if consumption grows.

The model estimates resistance in the UK for the WHO critical priority bacteria in three scenarios: low consumption, current consumption, and increased consumption. With a 10% year-on-year increase in consumption this is projected to reach around 25%. This trend is repeated in the other critical priority bacteria, Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae, with resistance to piperacillin/tazobactam increasing significantly in an increased consumption scenario. 

K. pneumoniae is expected to see the most dramatic increase in resistance, from 19.6% when last reported in 2022 to up to 41.8% in 2033. Interestingly, resistance in K. pneumoniae appears to be less related to consumption compared to other bacteria, with resistance increasing by a similar level (up to ~42%) in all three scenarios. This highlights that while reducing inappropriate antibiotic consumption overall remains critical to reducing resistance, it is not the only influencing factor and other strategies must also be implemented. 

These findings were presented in Airfinity exclusive industry leader roundtable: Combating AMR: Identifying, predicting, and reducing AMR burden. To see the full presentation click here, or email for more information.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022